北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
作者: Zhang, Li1; Ma, Shenglin2; Song, Xiangqun3; Han, Baohui4; Cheng, Ying5; Huang, Cheng6; Yang, Shujun7; Liu, Xiaoqing8; Liu, Yunpeng9; Lu, Shun10; Wang, Jie11; Zhang, Shucai12; Zhou, Caicun13; Zhang, Xiangwei14; Hayashi, Nobuya15; Wang, Mengzhao16; INFORM Investigators
刊名: LANCET ONCOLOGY
发表日期: 2012-05-01
DOI: 10.1016/S1470-2045(12)70117-1
卷: 13, 期:5, 页:466-475
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: QUALITY-OF-LIFE ; CLINICALLY SELECTED PATIENTS ; III TRIAL ; 1ST-LINE CHEMOTHERAPY ; FUNCTIONAL ASSESSMENT ; JAPANESE PATIENTS ; SUPPORTIVE CARE ; ADVANCED NSCLC ; CARBOPLATIN ; DOCETAXEL
英文摘要:

Background Maintenance treatment of patients with advanced non-small-cell lung cancer (NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing research. The aim of the randomised, double-blind, placebo-controlled, INFORM study was to investigate the efficacy, safety, and tolerability of the EGFR-tyrosine-kinase inhibitor gefitinib in the maintenance setting.

Methods Patients were aged 18 years or older, were of east Asian ethnic origin, had a life expectancy of more than 12 weeks, histologically or cytologically confirmed stage IIIb or IV NSCLC, a WHO performance status of 0-2, and had completed four cycles of first-line platinum-based doublet chemotherapy without disease progression or unacceptable toxic effects. Between Sept 28, 2008 and Aug 11, 2009, 296 patients were randomly assigned 1: 1 to receive either gefitinib (250 mg per day orally) or placebo (orally) within 3-6 weeks after chemotherapy until progression or unacceptable toxic effects. Randomisation was done via an interactive web response system with computer-generated randomisation codes. Our primary endpoint was progression-free survival assessed in the intention-to-treat population. This completed study is registered with Clinicaltrials.gov, number NCT00770588.

Findings Progression-free survival was significantly longer with gefitinib (n=148) than with placebo (148) (median progression-free survival 4.8 months [95% CI 3.2-8.5] vs 2.6 months [1.6-2.8]; hazard ratio [HR] 0.42, 95% CI 0.33-0.55; p<0.0001). Adverse events occurred more frequently with gefitinib than with placebo; the most common adverse events of any grade were rash (73 [50%] of 147 in the gefitinib group vs 14 [9%] of 148 in the placebo group), diarrhoea (37 [25%] vs 13 [9%]), and alanine aminotransferase increase (31 [21%] vs 12 [8%]). The most commonly reported grade 3 or 4 adverse event was alanine aminotransferase increase (3 [2%] of 147 in the gefitinib group, none of 148 in the placebo group). Ten of 147 (7%) patients given gefitinib and five of 148 (3%) patients given placebo had serious adverse events. Three deaths were thought to be related to treatment with gefitinib: one from interstitial lung disease; one from lung infection; and one from pneumonia.

Interpretation Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy. Clinicians should consider these data when making decisions about maintenance treatment in such patients.

语种: 英语
项目资助者: AstraZeneca
WOS记录号: WOS:000303508700038
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64045
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
2.Zhejiang Canc Hosp, Dept Radiat Therapy, Hangzhou, Zhejiang, Peoples R China
3.Guangxi Zhuang Autonomous Reg Tumour Hosp, Nanning, Peoples R China
4.Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China
5.Jilin Prov Tumour Hosp, Changchun, Peoples R China
6.Fujian Prov Tumor Hosp, Fuzhou, Peoples R China
7.Henan Prov Tumour Hosp, Dept Chemotherapy, Zhengzhou, Peoples R China
8.Peoples Liberat Army, Hosp 307, Dept Oncol, Beijing, Peoples R China
9.China Med Univ, Hosp 1, Shenyang, Peoples R China
10.Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China
11.AstraZeneca, Shanghai, Peoples R China
12.AstraZeneca KK, Osaka, Japan
13.Shanghai Chest Hosp, Med Ctr, Lung Tumour Clin, Shanghai, Peoples R China
14.Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
15.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Oncol, Shanghai 200092, Peoples R China
16.Peking Union Med Coll, Dept Resp Dis, Beijing 100021, Peoples R China

Recommended Citation:
Zhang, Li,Ma, Shenglin,Song, Xiangqun,et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial[J]. LANCET ONCOLOGY,2012,13(5):466-475.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Li]'s Articles
[Ma, Shenglin]'s Articles
[Song, Xiangqun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Li]‘s Articles
[Ma, Shenglin]‘s Articles
[Song, Xiangqun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace